| Title |
Anemia in chronic heart failure: Can we treat? What to treat?
|
|---|---|
| Published in |
Heart Failure Reviews, October 2011
|
| DOI | 10.1007/s10741-011-9283-x |
| Pubmed ID | |
| Authors |
Stephan von Haehling, Markus S. Anker, Ewa A. Jankowska, Piotr Ponikowski, Stefan D. Anker |
| Abstract |
Even though anemia is a significant comorbidity regularly observed in patients with chronic heart failure (HF), only in recent years systematic therapeutic research has been started. This article aims to review the aspects of anemia in chronic HF that are relevant for making treatment decisions, beginning with the definition of anemia and its incidence and prevalence of anemia in patients with chronic HF. Considering the etiology and prognostic impact of anemia in chronic HF, several treatment options will be considered. The latter are the application of erythropoiesis-stimulating agents (erythropoietin or darbepoetin alfa) or in the application of intravenous iron (e.g., iron carboxymaltose). According to the results seen in the FAIR-HF trial, iron supplementation should be particularly considered to improve symptoms and quality of life. Intravenous iron application may result in higher compliance and much faster treatment response than oral iron. The RED-HF study will show whether use of darbepoetin alfa in anemic patients with chronic HF will reduce the combined endpoint of death for any reason or hospitalization for heart failure. |
Mendeley readers
The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 2% |
| Unknown | 62 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 7 | 11% |
| Researcher | 7 | 11% |
| Other | 6 | 10% |
| Professor | 5 | 8% |
| Student > Bachelor | 5 | 8% |
| Other | 18 | 29% |
| Unknown | 15 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 52% |
| Nursing and Health Professions | 6 | 10% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Agricultural and Biological Sciences | 2 | 3% |
| Economics, Econometrics and Finance | 1 | 2% |
| Other | 2 | 3% |
| Unknown | 17 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 November 2023.
All research outputs
#7,409,093
of 22,653,392 outputs
Outputs from Heart Failure Reviews
#226
of 663 outputs
Outputs of similar age
#45,898
of 135,640 outputs
Outputs of similar age from Heart Failure Reviews
#3
of 5 outputs
Altmetric has tracked 22,653,392 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 663 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.9. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 135,640 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.